Treating prolactinoma can prevent autoimmune diseases

Cell Immunol. 2015 Apr;294(2):84-6. doi: 10.1016/j.cellimm.2014.11.002. Epub 2014 Nov 10.

Abstract

Prolactin (PRL) is a pleiotropic hormone; in addition to a wide variety of endocrine effects, PRL also exhibits immunostimulating effects. Therefore, there is increasing evidence linking PRL with a large number of systemic and organ specific autoimmune diseases. Herein, we report the case of an adolescent girl diagnosed with multiple sclerosis (MS) occurring in the context of untreated prolactinoma evolving since childhood. This raises the exciting question of the involvement of PRL in the pathogenesis of MS. It is likely that early treatment of hyperprolactinemia in this case would have significantly reduced the risk of developing MS or even prevented its occurrence.

Keywords: Autoimmune disease; Autoimmunity; Bromocriptine; Cabergoline; Hormones; Multiple sclerosis; Prolactin; Prolactinoma.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Cabergoline
  • Child
  • Ergolines / adverse effects
  • Ergolines / therapeutic use*
  • Female
  • Humans
  • Hyperprolactinemia / complications
  • Hyperprolactinemia / therapy
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / prevention & control*
  • Prolactin / blood*
  • Prolactinoma / complications
  • Prolactinoma / drug therapy*

Substances

  • Antineoplastic Agents
  • Ergolines
  • Prolactin
  • Cabergoline